Chris Burns
ampliaceo.bsky.social
Chris Burns
@ampliaceo.bsky.social
CEO of Amplia Therapeutics, a Melbourne, Australia, based biotech developing a pipeline of small molecule FAK inhibitors for cancer and fibrotic diseases. Our lead asset is narmafotinib currently in a Phase 2a trial in pancreatic cancer (NCT05355298).
New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma
October 8, 2025 at 11:23 PM
Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics

$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics
July 30, 2025 at 3:53 AM
Amplia Therapeutics has today announced the appointment of experienced oncologist and clinical trials specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer. Read the ASX Release: ampliatx.com/announcement...

#Amplia #pharma #clinicaltrials #cancer #oncology
May 12, 2025 at 12:49 AM
Looking forward to attending #BioKorea2025 in Seoul next week to present at the Global BIO Connection Session and meet with collaborators and potential partners.
May 1, 2025 at 2:03 AM
Very pleased that Amplia could support the poster session at the ANZGOG 2025 scientific meeting. #ATX #ovariancancer
March 6, 2025 at 7:00 AM
Really enjoying the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting. Great to connect with super collaborator Gwo Yaw Ho as well! #ANZGOG2025ASM #ovariancancer #ATX
March 5, 2025 at 10:50 PM
Congratulations to Dr Anne-Laure Puaux from @wehi-research.bsky.social for being awarded BioMelbourne’s Emerging Leadership Award. #biomelbwomen
February 10, 2025 at 11:25 PM
Today - on World Cancer Day - we're grateful to our research collaborators, whose expertise and dedication make our clinical trials possible. Equal gratitude goes to the trial participants, and their families, who share our hope of improving outcomes for patients. #WorldCancerDay #pancreaticcancer
February 4, 2025 at 6:39 AM
MILESTONE | Amplia Therapeutics has completed the planned enrolment of the ACCENT Phase 2a clinical trial, with full recruitment achieved two months ahead of schedule. Read the ASX release: www.ampliatx.com/pdf/f61a6ac4...

$ATX #clinicaltrial #pancreaticcancer #cancer #innovation
January 31, 2025 at 2:32 AM
Great to have Amplia's Director of Translational Science, Dr Terrie-Anne Cock, present a poster at the Keystone TME meeting. Also present, our amazing collaborator Dr Kendelle Murphy from the Garvan @garvaninstitute.bsky.social #KSMetastasis25 #pancreaticcancer
January 24, 2025 at 5:53 AM
Great to be visiting collaborators at UCSD Moores Cancer Center discussing narmafotinib and clinical potential in ovarian cancer.
January 17, 2025 at 6:03 PM
Great to be visiting collaborators at UCSD Moores Cancer Center discussing narmafotinib and clinical potential in ovarian cancer.
January 17, 2025 at 6:02 PM
At JPM25 in San Francisco. Lots of meetings with potential investors, partners and suppliers. Presenting our promising data from ongoing ACCENT trial in pancreatic cancer.
January 15, 2025 at 8:16 PM